van Wijk, J 2005 Quality rating: Fair

Design:

Study design: RCT DB Crossover

  • Run-in: NR
  • Setting: NR
  • Wash out: 42 days
  • Country: Netherlands

Sample: Number Screened/Eligible/Enrolled Number Withdrawn/Lost to follow-up/Analyzed

22/20/19 0/0/19

Inclusion criteria:

Patients aged 35–70 years, diagnosed with DM2.

Exclusion criteria:

Smokers, women of child-bearing potential, taking insulin treatment, current or previous treatment with TZD, HbA >9%, serum creatinin >200 mean mol/l, abnormal thyrotropin, apartate aminotransferase, or alanine aminotransferase >2 times the upper limit of normal, congestive cardiac failure, blood pressure >160/>95 mmHg, total cholestrol >8mmol/l and/or triglycerides >5 mmol/l, alcohol intake >3 units/day.

Comments:

Population:

  • Mean age: 60 years
  • Ethnicity: NR
  • Gender: 26% Female
  • Type 2 diabetes duration (SD): NR (NR) years

Intervention: monotherapy

Duration: 8 week

Table

Laboratory measures:

Table

P value NR if not specified.

From: Evidence Tables

Cover of Drug Class Review: Thiazolidinediones
Drug Class Review: Thiazolidinediones: Final Report Update 1 [Internet].
Norris SL, Carson S, Thakurta S, et al.
Portland (OR): Oregon Health & Science University; 2008 Aug.
Copyright © 2008, Oregon Health & Science University, Portland, Oregon.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.